Hope for Parkinson’s disease symptoms is found in late-stage drug study
Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, late-stage study showed that the drug significantly improved the ability of patients to manage daily tasks such as walking and eating.
AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal
Data from a late-stage study shows that treatment with flexible doses of ABBV's tavapadon reduced the burden of Parkinson's disease.
AbbVie's Parkinson's disease drug meets main goal in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on Monday. The study tested the safety and efficacy of flexible doses of the drug,
AbbVie Says Phase 3 TEMPO-2 Study Of Tavapadon In Early Parkinson's Disease Met Main Goal
Monday said Phase 3 TEMPO-2 study evaluating tavapadon in early Parkinson's disease met its primary goal. In the
AbbVie’s Phase III trial of Parkinson’s disease treatment meets primary endpoint
The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.
AbbVie's Parkinson's disease drug improves patient mobility in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out daily tasks such as eating and walking, months after the drugmaker disclosed its success in a separate study.
AbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study -- Update
AbbVie on Monday said a third late-stage study of its tavapadon drug candidate hit its key goals in the neurodegenerative disorder Parkinson's disease. AbbVie said tavapadon met the primary endpoint in the pivotal Phase 3 flexible-dose monotherapy trial,
Crain's Chicago Business18h
After one disappointment, AbbVie gets good news out of Cerevel buy
The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...
BioSpace2d
A Month After Stunning Schizophrenia Fail, AbbVie’s Other Cerevel Asset Shines Again
Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie ...
Outsourcing-pharma1d
AbbVie’s Parkinson’s disease monotherapy achieves positive phase 3 results
“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...
Betting Big On AbbVie: A Prescription For Growth And Dividends
AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...
clinicaladvisor.com1d
Tavapadon Beneficial for Early Parkinson Disease in Flexible-Dose Trial
Treatment with tavapadon led to a statistically significant improvement in motor function compared with placebo. Topline results were announced from a phase 3 trial evaluating tavapadon, a selective ...
AbbVie reports ‘positive’ results from Phase 3 TEMPO-2 trial
AbbVie (ABBV) announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose ...